Author:
Arnaud Laurent,van Vollenhoven Ronald
Publisher
Springer International Publishing
Reference131 articles.
1. 1 Esdaile JM. [Lupus. The disease with a thousand faces]. L’union medicale du Canada. 1991;120:357–358.
2. 2 Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014;13:1082–1089.
3. 3 Petri M, Barr SG, Zonana-Nach A, Magder L. Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. The Journal of rheumatology. 1999;26:502–3.
4. 4 Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930.
5. 5 van Vollenhoven RF, Voskuyl A, Morand E, Aranow C. Remission in SLE: closing in on the target. Ann Rheum Dis. 2015;74:2103–2106.